In what was reported as an all cash deal, in October 2104, Enantigen Therapeutics Inc ws acquired by OnCore Biopharma, Inc. a biotechnology company focused on the research, development and commercialization of oral treatments for chronic hepatitis B virus (HBV) infectio. OnCore was founded in 2012 by former executives of Pharmasset, Inc. after Pharmasset's acquisition by Gilead Sciences, Inc - both of which firms had been presviously SBIR Involved - Pharmasset before being acquired by Gilead in 2012 and Gilead, like so many piotech firms, during its startup days. OnCore Biopharma, Inc. had been organized around finding a cure for chronic hepatitis B virus infection. Eantigen Therapeutics, Inc., had similarly been working on novel drugs to treat life threatening infectious diseases with primary focus is on oral therapeutics for the treatment of Hepatitis B, Hepatitis C, Hepatocellular Carcinoma (HCC), and other viral related diseases.
